Bexagliflozin vs Tofogliflozin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline
Bexagliflozin · Brenzavvy
Marketed by Theracos and partners
NCT02558296 · Phase 3 · completed
This was a large randomized, quadruple-blind, placebo-controlled trial with 1,700 participants, and its primary HbA1c comparison at week 24 was statistically significant in favor of bexagliflozin. HbA1c is an approvable primary endpoint in type 2 diabetes, so the design and the result support strong evidence.
Next expected readout: March 2029 · NCT07547878 (registry estimate)
Reported efficacy
Change From Baseline in HbA1c at Week 60 (Baseline and Week 60): Change From Baseline in HbA1c at Week 60 (Baseline and Week 60): Bexagliflozin -0.7 percentage of glycated hemoglin (Standard Error 0.058) vs Glimepiride -0.66 percentage of glycated hemoglin (Standard Error 0.058) (met)
Result source: NCT02769481
Tofogliflozin · Apleway / Deberza
Marketed by Chugai Pharma and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Bexagliflozin | Tofogliflozin |
|---|---|---|
| HbA1c, change | -0.8% vs -0.4%−0.5 vs placeboNCT0255829623 other results
| —Not reported |
| Body weight, change (kg) | -3.0 vs -0.4−2.6 vs placeboNCT0255829614 other results
| —Not reported |
| HbA1c below 7% | —Not reported | —Not reported |
| Fasting plasma glucose, change | -2.5 vs -1.2−1.3 vs placeboNCT0325978910 other results
| —Not reported |
| 3-point MACE (% with event) | —Not reported | —Not reported |
HbA1c, change
- Bexagliflozin
- -0.8% vs -0.4%−0.5 vs placeboNCT02558296
23 other results
- -1.1% vs -0.6% NCT03259789
- -0.5% vs -0.1% NCT02715258
- -0.6% vs -0.3% NCT02836873
- -0.7% vs -0.7% NCT02769481
- -0.7% vs -0.8% NCT03115112
- -1.1% vs -0.6% NCT03259789
- -0.6% vs -0.4% NCT02836873
- -0.6% vs -0.2% NCT02836873
- -1% vs -0.5% NCT03259789
- -1.0% vs -0.3% NCT03259789
- -0.7% vs -0.2% NCT03259789
- -0.6% vs 0.2% NCT02390050
- -0.4% vs 0.2% NCT02390050
- -0.3% vs 0.2% NCT02390050
- -0.6% vs 0.2% NCT02390050
- -0.4% vs 0.1% NCT02390050
- -0.1% vs 0% NCT02390050
- -0.4% vs 0.2% NCT02390050
- -0.4% vs 0.1% NCT02390050
- -0.1% vs 0% NCT02390050
- -0.3% vs 0.2% NCT02390050
- -0.3% vs 0.1% NCT02390050
- -0.1% vs 0% NCT02390050
- Tofogliflozin
- —Not reported
Body weight, change (kg)
- Bexagliflozin
- -3.0 vs -0.4−2.6 vs placeboNCT02558296
14 other results
- -3.6 vs -1.1 NCT03259789
- -1.9 vs -1.1 NCT02715258
- -2.3 vs -0.6 NCT02836873
- -3.7 vs 0.6 NCT02769481
- -3.4 vs -0.8 NCT03115112
- -1.9 vs -0.1 NCT02390050
- -1.5 vs 0.0 NCT02390050
- -1.0 vs 0 NCT02390050
- -1.7 vs -0.1 NCT02390050
- -1.4 vs 0.0 NCT02390050
- -0.8 vs 0 NCT02390050
- -1.6 vs -0.1 NCT02390050
- -1 vs 0.0 NCT02390050
- -0.7 vs 0 NCT02390050
- Tofogliflozin
- —Not reported
HbA1c below 7%
- Bexagliflozin
- —Not reported
- Tofogliflozin
- —Not reported
Fasting plasma glucose, change
- Bexagliflozin
- -2.5 vs -1.2−1.3 vs placeboNCT03259789
10 other results
- -1.8 vs -1.4 NCT03115112
- -1.2 vs -0.1 NCT02390050
- -1.0 vs 0.1 NCT02390050
- -1.1 vs -0.1 NCT02390050
- -1.2 vs -0.1 NCT02390050
- -1.1 vs 0.1 NCT02390050
- -1.0 vs -0.1 NCT02390050
- -1.0 vs -0.1 NCT02390050
- -0.8 vs 0.1 NCT02390050
- -0.6 vs -0.1 NCT02390050
- Tofogliflozin
- —Not reported
3-point MACE (% with event)
- Bexagliflozin
- —Not reported
- Tofogliflozin
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Tofogliflozin: no structured comparison results are available for Type 2 Diabetes.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Bexagliflozin: 4 of 4 rows · Tofogliflozin: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Bexagliflozin |
|---|---|
| Dropout rate | 3.9%20 mga NCT02558296 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 16 more results15.5% NCT02769481 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 10.8%20 mg NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3 11.4%20 mg NCT02715258 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 6.3% NCT03115112 · Phase 3 3.2%20 mg NCT02836873 · Phase 3 9.2%20 mg NCT02390050 · Phase 2 · registry result, not featured evidence 5.6%10 mg NCT02390050 · Phase 2 · registry result, not featured evidence 6.9%5 mg NCT02390050 · Phase 2 · registry result, not featured evidence —Study 1: Bexagliflozin Alone NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy —Study 1: Bexagliflozin and Probene NCT03296800 · Phase 1 · registry result, not featured evidence · combination —Study 2: Bexagliflozin Alone NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy —Study 2: Bexagliflozin and Rrifamp NCT03296800 · Phase 1 · registry result, not featured evidence · combination —Study 3: Bexagliflozin Alone NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy —Study 3: Bexagliflozin and Verapam NCT03296800 · Phase 1 · registry result, not featured evidence · combination —Bexagliflozin Tablet Dosed in Fast NCT02820298 · Phase 1 · registry result, not featured evidence —Bexagliflozin Tablet Dosed in Fed NCT02820298 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | 0.8%20 mga NCT02558296 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 16 more results1.4% NCT02769481 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 1.9%20 mg NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3 —20 mg NCT02715258 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 2.6% NCT03115112 · Phase 3 0.6%20 mg NCT02836873 · Phase 3 —20 mg NCT02390050 · Phase 2 · registry result, not featured evidence —10 mg NCT02390050 · Phase 2 · registry result, not featured evidence —5 mg NCT02390050 · Phase 2 · registry result, not featured evidence —Study 1: Bexagliflozin Alone NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy —Study 1: Bexagliflozin and Probene NCT03296800 · Phase 1 · registry result, not featured evidence · combination —Study 2: Bexagliflozin Alone NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy —Study 2: Bexagliflozin and Rrifamp NCT03296800 · Phase 1 · registry result, not featured evidence · combination —Study 3: Bexagliflozin Alone NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy —Study 3: Bexagliflozin and Verapam NCT03296800 · Phase 1 · registry result, not featured evidence · combination —Bexagliflozin Tablet Dosed in Fast NCT02820298 · Phase 1 · registry result, not featured evidence —Bexagliflozin Tablet Dosed in Fed NCT02820298 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 33%20 mga NCT02558296 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 16 more results11.7% NCT02769481 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 1.9%20 mg NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3 0.7%20 mg NCT02715258 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 3.7% NCT03115112 · Phase 3 7%20 mg NCT02836873 · Phase 3 2.6%20 mg NCT02390050 · Phase 2 · registry result, not featured evidence 4.2%10 mg NCT02390050 · Phase 2 · registry result, not featured evidence 0%5 mg NCT02390050 · Phase 2 · registry result, not featured evidence 0%Study 1: Bexagliflozin Alone NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy 0%Study 1: Bexagliflozin and Probene NCT03296800 · Phase 1 · registry result, not featured evidence · combination 0%Study 2: Bexagliflozin Alone NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy 0%Study 2: Bexagliflozin and Rrifamp NCT03296800 · Phase 1 · registry result, not featured evidence · combination 0%Study 3: Bexagliflozin Alone NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy 0%Study 3: Bexagliflozin and Verapam NCT03296800 · Phase 1 · registry result, not featured evidence · combination 0%Bexagliflozin Tablet Dosed in Fast NCT02820298 · Phase 1 · registry result, not featured evidence 0%Bexagliflozin Tablet Dosed in Fed NCT02820298 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 20 mga hypoglycaemia 42% (placebo 43.4%) urinary tract infection 11.3% (placebo 10.6%) upper respiratory tract infection 9.9% (placebo 9.3%) NCT02558296 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 16 more resultshypoglycemia 16.9% nasopharyngitis 13.6% urinary tract infection 11.7% NCT02769481 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 20 mg nasopharyngitis 5.7% (placebo 8.2%) polydipsia 3.2% (placebo 2.5%) polyuria 3.2% (placebo 3.8%) NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3 20 mg polyuria 7.2% (placebo 2.9%) urinary tract infection 5.1% (placebo 2.9%) abdominal pain 3.6% (placebo 7.2%) NCT02715258 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 20 mg hypoglycaemia 25.5% (placebo 25.8%) polyuria 7.6% (placebo 4.5%) nasopharyngitis 7% (placebo 8.4%) NCT02836873 · Phase 3 20 mg hypoglycemia 5.3% (placebo 1.4%) dysuria 3.9% (placebo 1.4%) nasopharyngitis 3.9% (placebo 4.2%) NCT02390050 · Phase 2 · registry result, not featured evidence 10 mg nasopharyngitis 5.6% (placebo 4.2%) pharyngitis 4.2% (placebo 0%) arthralgia 2.8% (placebo 0%) NCT02390050 · Phase 2 · registry result, not featured evidence 5 mg nasopharyngitis 6.9% (placebo 4.2%) diarrhea 2.8% (placebo 2.8%) dizziness 2.8% (placebo 1.4%) NCT02390050 · Phase 2 · registry result, not featured evidence diarrhea 0% gastrointestinal sounds abnormal 0% laceration 0% NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy diarrhea 6.3% gastrointestinal sounds abnormal 6.3% laceration 0% NCT03296800 · Phase 1 · registry result, not featured evidence · combination diarrhea 0% gastrointestinal sounds abnormal 0% laceration 0% NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy diarrhea 0% gastrointestinal sounds abnormal 0% laceration 0% NCT03296800 · Phase 1 · registry result, not featured evidence · combination laceration 6.3% presyncope 6.3% diarrhea 0% NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy diarrhea 0% gastrointestinal sounds abnormal 0% laceration 0% NCT03296800 · Phase 1 · registry result, not featured evidence · combination dizziness 4.2% headache 4.2% nasal congestion 4.2% NCT02820298 · Phase 1 · registry result, not featured evidence chest discomfort 4.3% dizziness 4.3% headache 4.3% NCT02820298 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 13 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Bexagliflozin
show 23 more results
show 14 more results
show 10 more results
show 2 more results
show 6 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bexagliflozin's landscape · Tofogliflozin's landscape